
100,0
90,0
80,0
70,0
60,0
50,0
40,0
30,0
20,0
10,0
0,0
% dissous
1000,0
900,0
800,0
700,0
600,0
500,0
400,0
300,0
200,0
100,0
0,0
0
0,5
1
1,5
2
2,5
3
Temps (h)

FIG.1

9. Granulat nach einem beliebigen der Ansprüche 1 bis 7 zur Verwendung bei der Behandlung von Pathologien, die mindestens die sehr schnelle *in vivo*-Bereitstellung des GHB erfordern.

10. Granulat nach einem beliebigen der Ansprüche 1 bis 7 zur Verwendung bei der Behandlung nach Anspruch 9, **dadurch gekennzeichnet, dass** die Pathologie die Narkolepsie ist.

11. Granulat nach einem beliebigen der Ansprüche 1 bis 7 zur Verwendung bei der Behandlung nach Anspruch 9, **dadurch gekennzeichnet, dass** die Pathologie der Alkoholentzug ist.

Claims

1. Granule comprising a solid core carrying an active ingredient, said active ingredient being selected from among gamma-hydroxy butyric acid or one of the pharmaceutically acceptable salts thereof, said granule **characterized in that** it is composed of:

   - 15-25 % solid core,
   - 50-60 % active ingredient;
   - 5-15 % sodium bicarbonate, gas generator;
   - 2-18 % magnesium aluminometasilicate, diluent;
   - 3-10 % shellac, binder;
   - 3-6 % coating membrane.

2. The granule according to claim 1, wherein the solid core is selected from the group formed by polyols, gums, silica derivatives, calcium or potassium derivatives, mineral compounds such as dicalcium phosphates, tricalcium phosphates and calcium carbonates, sucrose, cellulose derivatives in particular microcrystalline cellulose, ethyl cellulose and hydroxypropyl methylcellulose, starch and mixtures thereof.

3. The granule according to any of claims 1 to 2, wherein the membrane is composed of coating excipients for immediate release.

4. The granule according to any of claims 1 to 2, wherein the membrane is composed of coating excipients for sustained release.

5. The granule according to any of claims 1 to 4, **characterized in that** it further comprises a colouring agent.

6. The granule according to any of claims 1 to 5, **characterized in that** it further comprises a sweetener.

7. The granule according to any of claims 1 to 6, **characterized in that** it further comprises a flavouring agent.

8. Pharmaceutical composition comprising a mixture of granules according to any of claims 1 to 7, wherein said mixture is composed of two groups of granules (A) and (B), granules (A) and granules (B) having different release kinetics of active ingredient.

9. Application of the granule according to any of claims 1 to 7 for use in the treatment of pathologies requiring at least very rapid *in vivo* availability of GHB.

10. Application of the granule according any of claims 1 to 7 for use in the treatment according to claim 9, **characterized in that** the pathology is narcolepsy.

11. Application of the granule according any of claims 1 to 7 for use in the treatment according to claim 9, **characterized in that** the pathology is alcohol withdrawal.


100,0
90,0
80,0
70,0
60,0
50,0
40,0
30,0
20,0
10,0
0,0
% dissous
0
0,5
1
1,5
2
2,5
3
Temps (h)

FIG.2


100,0
90,0
80,0
70,0
60,0
50,0
40,0
30,0
20,0
10,0
0,0
% dissous
700,0
600,0
500,0
400,0
300,0
200,0
100,0
0,0
0
0,5
1
1,5
2
2,5
3
Temps (h)

FIG.3



FIG.4



FIG.5

RÉFÉRENCES CITÉES DANS LA DESCRIPTION

Cette liste de références citées par le demandeur vise uniquement à aider le lecteur et ne fait pas partie du document de brevet européen. Même si le plus grand soin a été accordé à sa conception, des erreurs ou des omissions ne peuvent être exclues et l'OEB décline toute responsabilité à cet égard.

Documents brevets cités dans la description

- US 5594030 A **[0006]**
- EP 0635265 A **[0007]**
- US 2006210630 A **[0008]**
- WO 2010055260 A **[0010]**
- WO 2011018583 A **[0014]**

Littérature non-brevet citée dans la description

- **PALATINI et al.** *European Journal of Clinical Pharmacology*, 1993 **[0016]**
- **WAGNER JG ; NELSON E.** *J. Pharm. Sci.*, 1968, vol. 53 (11), 1392-1403 **[0135]**